AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca has initiated a Phase I, open-label clinical study titled ‘AZD5305 hADME in Patients With Advanced Solid Malignancies.’ The study aims to evaluate the absolute bioavailability and the absorption, distribution, metabolism, and excretion (ADME) of Saruparib (AZD5305) in patients with advanced solid malignancies. This research is significant as it seeks to understand the pharmacokinetics of Saruparib, potentially leading to improved treatment options for patients with these conditions.
The intervention being tested includes Saruparib (AZD5305), a PARP inhibitor, administered both orally and intravenously. The study also involves the use of a radiolabeled microtracer, [14C]-AZD5305, to assess the drug’s pharmacokinetic properties.
The study design is interventional and non-randomized, involving a single-group assignment with no masking. Approximately eight patients will participate, undergoing treatment in two parts: Part A focuses on oral administration and Part B on intravenous administration. The primary purpose is basic science, aiming to gather foundational data on the drug’s behavior in the body.
The study began on April 2, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on July 18, 2025. These dates are crucial as they mark the progression and expected milestones of the study, providing timelines for potential results and subsequent phases.
The market implications of this study could be significant for AstraZeneca’s stock performance and investor sentiment. Positive outcomes may enhance the company’s position in the oncology market, particularly in the development of PARP inhibitors. The study’s progress and results could also influence the competitive landscape, as other pharmaceutical companies are also exploring similar treatments.
The study is currently ongoing, with further details available on the ClinicalTrials portal.